Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 6/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18252816 | 0.89 | FFAR1 (0.47) | FFAR1FFAR4THRATHRBPPARA | |
| SCHEMBL18255658 | 0.82 | FFAR1 (0.50) | FFAR1FFAR4THRATHRBPPARA | |
| SCHEMBL1015795 | 0.78 | LMNA (0.54) | FFAR1FFAR4THRATHRBTACR1 | |
| SCHEMBL24951048 | 0.77 | FFAR1 (0.46) | FFAR1FFAR4THRATHRBPPARA | |
| SCHEMBL24433933 | 0.76 | CYP3A4 (0.41) | TACR1LMNAALDH1A1CCR2 | |
| SCHEMBL30151169 | 0.74 | FFAR4 (0.48) | FFAR1FFAR4THRATHRBPPARA | |
| SCHEMBL17310946 | 0.72 | RXRA (0.51) | FFAR1FFAR4THRATHRBTACR1 | |
| SCHEMBL21900404 | 0.71 | RXRA (0.39) | TACR1LMNAALDH1A1CCR2 | |
| SCHEMBL30151149 | 0.71 | THRA (0.50) | FFAR1FFAR4THRATHRBLMNA | |
| SCHEMBL30151135 | 0.71 | THRA (0.47) | FFAR1FFAR4THRATHRBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190275015-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | FFAR1 563/4885FFAR4 747/4885THRA 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.